Medicare announces new payment rates for COVID-19 monoclonal antibody infusions
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase payment to administer them in most other care settings to $450 from $310 to better align payment with provider costs, the Centers for Medicare & Medicaid Services announced yesterday. CMS is updating its COVID-19 toolkits and coding resources to reflect the new payment rates.
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Feb. 19 urged the Health Resources and Services Administration to extend the…
Headline
A JAMA study published Feb. 18 found that 10% of Medicare Advantage beneficiaries — approximately 2.9 million — have needed to find other health coverage for…
Headline
The AHA Feb. 17 submitted a comment letter responding to the Centers for Medicare & Medicaid Services’ proposed rule that would prohibit hospitals…
Headline
The Minnesota Court of Appeals Feb. 17 affirmed a lower court decision in ruling that the state’s 340B contract pharmacy law is not preempted by federal law.…
Headline
The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program. The RFI said HHS’ Health Resources and…